Related Experiment Videos
Effectiveness of screening for prostate cancer
1Department of Health, Housing and Community Services, Canberra.
Australian Family Physician
|August 1, 1993
Summary
Current evidence does not support routine digital rectal exams for prostate cancer screening in asymptomatic men. Tumor markers like prostate specific antigen and transrectal ultrasound are also not recommended for general screening.
Area of Science:
- Urology
- Oncology
- Preventive Medicine
Background:
- Prostate cancer is a significant health concern.
- Screening methods aim to detect cancer early.
- Assessing the efficacy of screening tests is crucial.
Purpose of the Study:
- To evaluate the effectiveness of digital rectal examination (DRE) for prostate cancer screening.
- To determine the utility of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in routine screening.
- To provide evidence-based recommendations on prostate cancer screening practices.
Main Methods:
- Review of existing scientific literature and clinical trial data.
- Analysis of evidence regarding digital rectal examination efficacy.
- Assessment of data on prostate specific antigen and transrectal ultrasound for screening.
Main Results:
- Insufficient evidence exists to recommend for or against routine DRE for asymptomatic men.
- Prostate specific antigen (PSA) is not recommended for routine screening.
- Transrectal ultrasound (TRUS) is not advised for routine screening purposes.
Conclusions:
- Routine DRE is not currently supported by sufficient evidence for prostate cancer screening.
- Tumor markers like PSA and TRUS should not be used for general screening.
- Further research may be needed to clarify optimal screening strategies for prostate cancer.